Enveric Biosciences, Inc.
ENVBHealthcare|Biotechnology|US
$1.42
+0.00 (+0.28%)
DCF Value
$12.40
Tangible Book / Share
$2.03
Cash / Share
$2.08
Financials
Financial Snapshot
Market Cap
$6.4M
Enterprise Value
-$1.9M
Revenue (TTM)
$0.00
Net Income (TTM)
-$8.7M
Cash & Investments
$8.3M
Net Cash
$8.3M
Free Cash Flow (TTM)
-$8.6M
Operating CF (TTM)
-$8.6M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$8.3M
Quarterly Burn
$2.1M
Monthly Burn
$713.4K
Est. Runway
~3.9 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $1.5M | $4.9M | $1.4M | $431.4K | $1.6M | $17.4M | $17.7M | $2.3M | $2.2M | $4.7M | $8.3M | |
| Operating Cash Flow | -$2.7M | -$2.7M | -$2.6M | -$647.9K | -$3.9M | -$11.5M | -$17.1M | -$14.1M | -$7.7M | -$8.1M | -$8.6M | |
| Free Cash Flow | -$6.4M | -$2.7M | -$2.6M | -$647.9K | -$3.9M | -$12.3M | -$17.7M | -$14.1M | -$7.7M | -$8.1M | -$8.6M | |
| Capital Expenditure | -$3.7M | -$4.8K | $0.00 | $0.00 | -$44.1K | -$864.7K | -$584.2K | -$5.2K | $0.00 | $0.00 | -$4.00 | |
| Financing Cash Flow | $8.8M | $7.1M | $2.7M | $560.0K | $5.5M | $24.9M | $18.2M | -$1.3M | $7.7M | $10.6M | $14.0M |
R&D Spending
R&D (TTM)
$2.5M
R&D Intensity
—
R&D Growth vs Prior
-11.0%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $36.1M | $48.6M | $43.0M | $39.9M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $0.00 | $0.00 | $0.00 | $0.00 | $174.1K | $4.8M | $8.0M | $7.3M | $2.8M | $2.8M | $2.5M | |
| R&D % of Revenue | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — | — | |
| SG&A | $9.0M | $18.5M | $10.8M | $12.2M | $5.3M | $20.5M | $11.5M | $8.8M | $6.5M | $5.8M | $6.1M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $36.1M | $48.6M | $43.0M | $39.9M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $29.6M | $38.4M | $34.0M | $31.8M | $120.9K | $681.6K | $435.2K | $408.0K | $337.5K | $200.9K | $153.9K | |
| Gross Profit | $6.5M | $10.2M | $9.0M | $8.2M | -$120.9K | -$681.6K | -$435.2K | -$408.0K | -$337.5K | -$200.9K | -$153.9K | |
| R&D | $0.00 | $0.00 | $0.00 | $0.00 | $174.1K | $4.8M | $8.0M | $7.3M | $2.8M | $2.8M | $2.5M | |
| SG&A | $9.0M | $18.5M | $10.8M | $12.2M | $5.3M | $20.5M | $11.5M | $8.8M | $6.5M | $5.8M | $6.1M | |
| Operating Income | -$5.4M | -$12.0M | -$7.1M | -$6.3M | -$5.6M | -$25.9M | -$20.0M | -$16.4M | -$9.6M | -$8.8M | -$8.7M | |
| Interest Expense | $751.1K | $575.0K | $729.9K | $691.1K | $445.3K | $10.3K | $5.2K | $3.7K | $0.00 | $106.00 | $845.00 | |
| Pretax Income | -$6.5M | -$11.5M | -$10.5M | -$5.2M | -$6.9M | -$56.4M | -$20.0M | -$17.3M | -$9.6M | -$8.8M | -$8.7M | |
| Net Income | -$2.8M | -$9.1M | -$16.9M | -$5.6M | -$6.9M | -$49.0M | -$18.5M | -$17.3K | -$9.6M | -$12.1M | -$8.7M | |
| EPS (Diluted) | -12770.04 | -36347.76 | -42616.68 | -2543.88 | -666.00 | -1244.28 | -156.00 | -97.08 | -228.48 | -36.24 | -16.46 | |
| EBITDA | -$4.4M | -$7.7M | -$6.9M | -$2.3M | -$6.3M | -$55.7M | -$19.5M | -$16.9M | -$9.2M | -$8.6M | -$8.6M | |
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.04 | 0.17 | 0.18 | 0.04 | 0.33 | 3.99 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.4M | $4.9M | $1.4M | $431.4K | $1.6M | $17.4M | $17.7M | $2.3M | $2.2M | $4.7M | $8.3M | |
| Short-Term Investments | $82.9K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $10.1M | $14.6M | $10.1M | $7.6M | $2.3M | $17.7M | $18.4M | $3.6M | $2.7M | $4.9M | $8.8M | |
| Total Assets | $39.5M | $52.2M | $29.6M | $25.0M | $4.1M | $26.7M | $19.6M | $4.3M | $3.1M | $5.1M | $8.9M | |
| Total Current Liabilities | $12.7M | $30.4M | $14.7M | $14.4M | $681.3K | $2.1M | $4.0M | $2.3M | $1.5M | $918.4K | $861.5K | |
| Long-Term Debt | $1.5M | $2.4M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $27.8M | $32.7M | $18.9M | $14.4M | $681.3K | $4.4M | $4.0M | $2.3M | $1.5M | $918.4K | $861.5K | |
| Stockholders' Equity | $11.7M | $19.4M | $10.8M | $10.6M | $3.4M | $22.3M | $14.7M | $2.0M | $1.6M | $4.2M | $8.1M | |
| Retained Earnings | -$3.8M | -$15.0M | -$34.5M | -$40.5M | -$11.8M | -$60.7M | -$79.2M | -$96.5M | -$106.1M | -$114.8M | -$119.5M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.7M | -$2.7M | -$2.6M | -$647.9K | -$3.9M | -$11.5M | -$17.1M | -$14.1M | -$7.7M | -$8.1M | -$8.6M | |
| Capital Expenditure | -$3.7M | -$4.8K | $0.00 | $0.00 | -$44.1K | -$864.7K | -$584.2K | -$5.2K | $0.00 | $0.00 | -$4.00 | |
| Free Cash Flow | -$6.4M | -$2.7M | -$2.6M | -$647.9K | -$3.9M | -$12.3M | -$17.7M | -$14.1M | -$7.7M | -$8.1M | -$8.6M | |
| Investing Cash Flow | -$6.6M | -$808.9K | -$3.6M | $0.00 | -$44.1K | $2.2M | -$584.2K | $11.7K | $0.00 | $0.00 | $0.00 | |
| Financing Cash Flow | $8.8M | $7.1M | $2.7M | $560.0K | $5.5M | $24.9M | $18.2M | -$1.3M | $7.7M | $10.6M | $14.0M | |
| Issuance of Stock | $5.0M | $4.9M | $6.3M | $0.00 | $488.0K | $21.6M | $17.2M | $0.00 | $2.3M | $10.6M | $14.0M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$1.1M | $1.1M | $0.00 | $0.00 | |
| Net Debt Issuance | $3.8M | $0.00 | -$2.0M | $538.0K | $1.7M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $1.5M | $7.1M | $1.3M | $0.00 | $2.0M | $12.6M | $2.6M | $2.2M | $1.6M | $827.3K | $641.0K | |
| Net Change in Cash | -$498.1K | $3.5M | -$3.5M | -$1.3M | $1.5M | $15.8M | $367.9K | -$15.4M | -$47.0K | $2.4M | $5.4M |
Dilution Tracker
Shares outstanding grew 3390.7% over 5 years — significant dilution
Shares Outstanding
4M
5-Year Share Growth
+3390.7%
Stock Issuance (TTM)
$14.0M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.04 | 0.17 | 0.18 | 0.04 | 0.33 | 3.99 | |
| Change vs Prior % | — | 14.7% | 58.4% | 456.3% | 335.3% | 310.5% | 340.0% | 3.9% | -76.7% | 698.7% | 1091.2% | |
| Stock Issuance | $5.0M | $4.9M | $6.3M | $0.00 | $488.0K | $21.6M | $17.2M | $0.00 | $2.3M | $10.6M | $14.0M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$1.1M | $1.1M | $0.00 | $0.00 | |
| Stock Based Comp. | $1.5M | $7.1M | $1.3M | $0.00 | $2.0M | $12.6M | $2.6M | $2.2M | $1.6M | $827.3K | $641.0K |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 18.1% | 21.1% | 20.9% | 20.4% | — | — | — | — | — | — | — | |
| Operating Margin % | -14.9% | -24.6% | -16.6% | -15.8% | — | — | — | — | — | — | — | |
| Net Margin % | -7.7% | -18.7% | -39.3% | -14.0% | — | — | — | — | — | — | — | |
| EBITDA Margin % | -12.2% | -15.8% | -16.1% | -5.7% | — | — | — | — | — | — | — | |
| FCF Margin % | -17.7% | -5.7% | -6.0% | -1.6% | — | — | — | — | — | — | — | |
| ROE % | -23.8% | -46.7% | -157.1% | -52.8% | -201.0% | -219.6% | -126.1% | -0.9% | -601.1% | -290.4% | -168.1% | |
| ROA % | -7.0% | -17.4% | -57.0% | -22.4% | -167.6% | -183.3% | -94.6% | -0.4% | -310.6% | -238.1% | -97.6% | |
| ROIC % | -7.6% | -35.6% | -35.5% | -40.8% | -164.5% | -91.0% | -118.3% | -840.8% | -604.7% | -210.0% | -108.0% | |
| R&D / Revenue % | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — | — |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 126.2% | 34.4% | -11.5% | -7.2% | -100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 13.7% | 56.6% | -12.3% | -9.3% | -101.5% | -463.9% | 36.2% | 6.2% | 17.3% | 40.5% | |
| Operating Income | -187.6% | -122.5% | 40.3% | 11.5% | 11.2% | -361.9% | 23.1% | 17.6% | 41.4% | 8.9% | |
| Net Income | -47.1% | -226.4% | -86.2% | 66.8% | -22.5% | -613.5% | 62.2% | 99.9% | -55273.2% | -26.7% | |
| EPS (Diluted) | -24.9% | -184.6% | -17.2% | 94.0% | 73.8% | -86.8% | 87.5% | 37.8% | -135.4% | 84.1% | |
| Operating Cash Flow | 26.4% | -1.4% | 6.4% | 74.7% | -500.3% | -194.6% | -49.7% | 17.8% | 45.2% | -5.4% | |
| Free Cash Flow | -19.3% | 57.1% | 6.6% | 74.7% | -507.1% | -213.3% | -43.9% | 20.5% | 45.2% | -5.4% | |
| R&D Expense | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 2650.9% | 67.6% | -9.7% | -60.8% | -2.1% | |
| SG&A Expense | 54.5% | 106.4% | -41.7% | 13.1% | -56.4% | 284.7% | -43.8% | -23.6% | -26.6% | -10.2% | |
| Total Assets | 185.6% | 32.1% | -43.2% | -15.6% | -83.6% | 552.2% | -26.8% | -78.0% | -28.3% | 65.3% | |
| Book Value / Share | 3728.6% | 45.4% | -65.1% | -82.3% | -92.6% | 59.1% | -84.1% | -87.9% | 249.5% | -67.2% | |
| Debt | -19.3% | 42.8% | -27.5% | -6.3% | -100.0% | 0.0% | -63.8% | -100.0% | 0.0% | 0.0% | |
| Diluted Shares | 17.8% | 14.7% | 58.4% | 456.3% | 335.3% | 310.5% | 340.0% | 3.9% | -76.7% | 698.7% |
Valuation
P/E (TTM)At Loss
P/S0.00
10Y Low / Med / High1.45 / 14.35 / 35.34
P/B0.70
10Y Low / Med / High0.29 / 16.87 / 109.54
EV/EBITDA0.22
EV/Revenue0.00
10Y Low / Med / High1.53 / 14.40 / 35.44
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$12.40
Tangible Book / Share
$2.03
Net Current Assets / Share
$1.77
Graham Net-Net
$1.86
Cash / Share
$2.08
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -458.81 | -76.76 | -3.68 | -31.98 | -57.57 | -6.73 | -2.40 | -2.41 | -0.28 | -0.10 | -0.09 | |
| P/S Ratio | 35.34 | 14.35 | 1.45 | 4.49 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 109.54 | 35.87 | 5.78 | 16.87 | 107.63 | 14.77 | 4.42 | 21.52 | 1.70 | 0.29 | 0.70 | |
| EV/EBITDA | -290.27 | -91.19 | -9.54 | -81.32 | -58.12 | -5.60 | -2.42 | -2.36 | -0.05 | 0.40 | 0.22 | |
| EV/Revenue | 35.44 | 14.40 | 1.53 | 4.60 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-16.42
Distress
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $10.0M | $15.0M | $25.0M |
| Net Income | -$105.4M | -$37.4M | -$14.5M |
| EPS | $-315.00 | $-111.60 | $-43.20 |
| # Analysts (EPS) | 1 | 1 | 1 |
Dividends
Frequency
Irregular
Recent Payments
| Ex-Date | Pay Date | Amount | Frequency |
|---|---|---|---|
| Apr 23, 2008 | $0.02 | Irregular |